Sapir Alex 4

What Happened

• Alex Sapir, President & Chief Executive Officer of Fulcrum Therapeutics (FULC), received a derivative award: options covering 650,000 shares reported on Feb 2, 2026. The reported transaction price is $0.00 (standard for option grants on Form 4); this is an award (not an open-market purchase or sale) and does not represent an immediate cash sale or acquisition of underlying shares.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (timely).
• Reported amount: 650,000 option shares; transaction price shown as $0.00; transaction code A (award).
• Vesting: Options vest in equal quarterly installments over four years beginning January 1, 2026, subject to Sapir’s continued service (footnote disclosure).
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax withholding, or exercise/cashless sale noted in this filing.

Context

• This filing documents an option grant (a derivative award). Such grants provide potential future equity if vesting and any exercise conditions are met; they are common compensation tools and do not necessarily indicate immediate buying or selling of stock. The Form 4 does not disclose strike/exercise price or immediate economic value of the award.